Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 27, 2024 for the Memorial Day holiday. Have a healthy, happy holiday.

Hide

COVID-19, flu, and RSV combination testing

Know more, sooner, with COVID-19 and respiratory molecular combination testing

SARS-CoV-2 (COVID-19), influenza, RSV, and other respiratory viruses can present with similar symptoms such as fever, cough, and shortness of breath. For at-risk groups1-3 or patients with a more acute illness, an expedited diagnosis is crucial, so treatment can be initiated while it’s most effective.1-3 That’s why it’s important to test for each of these illnesses at the same time.

Testing that supports a faster diagnosis

When a patient presents in-office with respiratory illness symptoms, send the specimen directly to Quest for the convenience of combination testing. Our SARS-CoV-2 (COVID-19) and respiratory molecular combination tests use a single specimen to test for common respiratory viruses, providing timely results to help you develop an appropriate care plan.

Why choose SARS-CoV-2 (COVID-19) and respiratory molecular combination tests for your patients

Combination testing options from Quest Diagnostics

Other respiratory testing options

Panel components may be ordered separately.

PSC testing availability

SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT combination test is now available for collection at Quest Patient Service Centers (PSCs) for patients with mild symptoms.
39992-50-50.jpg

COVID-19 testing statements

  • The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
  • All tests have been authorized by FDA under EUAs for use by authorized laboratories;
  • The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
  • The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses, pathogens; and,
  • All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.


References

  1. CDC. Factors that affect your risk of getting very sick from COVID-19. Updated October 19, 2022. Accessed October 25, 2022. https://www.cdc.gov/coronavirus/2019-ncov/your-health/risks-getting-very-sick.html
  2. CDC. Flu treatment. Updated October 11, 2022. Accessed October 25, 2022. https://www.cdc.gov/flu/treatment/index.html
  3. CDC. RSV. Updated December 18, 2020. Accessed October 20, 2022. https://www.cdc.gov/rsv/index.html
  4. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751. doi:10.1093/cid/ciaa508

Questions?

For more information on our combination testing solutions, or to set up a Quest account, connect with a Quest representative.

Contact us